Understanding the mechanisms underlying increased sensitivity of cohesin-deficient cells to agents like HMA or BET inhibitors, or how combination therapeutics could be employed, might lead to tailored therapeutics for cohesin mutant cancers. This evidence concerns the gene DNER and cancer.